Presentation is loading. Please wait.

Presentation is loading. Please wait.

The results of the analysis for rates of symptomatic IDH, asymptomatic IDH, and symptoms alone remained consistent with the primary analysis. The results.

Published byKlaudia Piasecka Modified over 5 years ago

Similar presentations

Presentation on theme: "The results of the analysis for rates of symptomatic IDH, asymptomatic IDH, and symptoms alone remained consistent with the primary analysis. The results."— Presentation transcript:

1 The results of the analysis for rates of symptomatic IDH, asymptomatic IDH, and symptoms alone remained consistent with the primary analysis. The results of the analysis for rates of symptomatic IDH, asymptomatic IDH, and symptoms alone remained consistent with the primary analysis. Symptomatic IDH rate did not differ between the run-in and the biofeedback period (P=0.12), but decreased between the run-in and the control period (P=0.01). There was no difference between the biofeedback and the control period (P=0.29). Asymptomatic IDH rate did not differ between the run-in and the biofeedback period (P=0.77) or the run-in and the control period (P=0.83); there were no differences between the biofeedback and the control period (P=0.64). Symptoms alone rate did not differ between the run-in and the biofeedback period (P=0.20) or the run-in and the control period (P=0.64); there were no differences between the biofeedback and the control period (P=0.37). IDH, intradialytic hypotension. Kelvin C.W. Leung et al. CJASN 2017;12: ©2017 by American Society of Nephrology

Download ppt "The results of the analysis for rates of symptomatic IDH, asymptomatic IDH, and symptoms alone remained consistent with the primary analysis. The results."

Similar presentations

Relationship between serum sodium after racing and the weight change (in %) during exercise in 2135 athletes who competed in endurance events. •, asymptomatic.

Relationship between serum sodium after racing and the weight change (in %) during exercise in 2135 athletes who competed in endurance events. •, asymptomatic.
Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.

Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
Suggested approach to patients with dabigatran-associated bleeding

Suggested approach to patients with dabigatran-associated bleeding
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.

Probability of cumulative incidence of ESRD, disease-related death, or death from other cause for the entire cohort. Probability of cumulative incidence.
Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.

Adjusted rate ratios of hospital days and admissions for blacks and Hispanics compared with whites by age group. Adjusted rate ratios of hospital days.
Conceptual model of the natural history of diabetic kidney disease.

Conceptual model of the natural history of diabetic kidney disease.
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Effects of hemodialysis on cardiac function

Effects of hemodialysis on cardiac function
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.

Three-year cumulative incidence of a gout diagnosis presented by level of kidney function and sex. Three-year cumulative incidence of a gout diagnosis.
PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:
Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.

Incidence of in-hospital mortality rates are lower in rapid correction rate group versus slow correction rate group but not significantly different by.
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.

Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.
Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.

Kaplan–Meier curve for technique survival censored for death, transplantation, and program exit for patient choice for all individuals commencing home.
Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.
Drug levels during the course of a dosing interval.

Drug levels during the course of a dosing interval.
(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E

(A) Mean (SD) serum continuous erythropoietin receptor activator (C. E
Seven-year cumulative incidence of ESRD according to baseline creatinine clearance (Ccr) and result of urine test for proteinuria (19). Seven-year cumulative.

Seven-year cumulative incidence of ESRD according to baseline creatinine clearance (Ccr) and result of urine test for proteinuria (19). Seven-year cumulative.

Similar presentations

Ads by Google